当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.

Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.

Abstract：

:The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobilization with CE (CY 4 g/m(2) on day 1 and etoposide 200 mg/m(2) on days 1-3). The rhG-CSF dose was 10 microg/kg/day for all patients. Both groups were comparable in terms of sex, age and number of previously given different chemotherapy regimens. Duration of neutropenia, CD34(+) cell count on the first day of apheresis and numbers of aphereses were not statistically different between the two arms. However, the number of doses of rhG-CSF up to the first cycle of apheresis procedures was significantly lower in the late group than in the early group (P=0.005). The median number of total CD34(+) cells collected was 10.54 x 10(6)/kg (range 0.11-37.27) in the early group and 10.81 x 10(6)/kg (range 0.17-49.83) in the late group of rhG-CSF (P=0.781). We conclude that PBSC mobilization after late use of rhG-CSF is an effective approach and therefore, in routine clinical practice, late rhG-CSF may be used for PBSC collections after chemotherapy-based mobilization regimens in this cost-conscious era.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Ozcelik T,Topcuoglu P,Beksac M,Ozcan M,Arat M,Biyikli Z,Bakanay SM,Ilhan O,Gurman G,Arslan O,Demirer T

doi

10.1038/bmt.2009.161

subject

Has Abstract

pub_date

2009-12-01 00:00:00

pages

779-83

issue

12

eissn

0268-3369

issn

1476-5365

pii

bmt2009161

journal_volume

44

pub_type

杂志文章,多中心研究,随机对照试验

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

    abstract：:The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate- and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 19...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701272

    authors： Moreau P,Milpied N,Voillat L,Colombat P,Mahé B,Rapp MJ,Moreau A,Dupas B,Bulabois CE,Juge-Morineau N,Harousseau JL

    更新日期：1998-06-01 00:00:00

  • Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation.

    abstract：:Acute inflammatory demyelinating polyneuropathy (AIDP) appeared in two patients following allogeneic bone marrow transplantation (BMT). In one transplanted patient (but not in the donor) T cells were sensitized against peripheral nervous system myelin. This could reflect a change in the T cell repertoire in a differen...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Eliashiv S,Brenner T,Abramsky O,Shahin R,Agai E,Naparstek E,Steiner I

    更新日期：1991-10-01 00:00:00

  • Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation.

    abstract：:We retrospectively analyzed red blood cell (RBC) support and alloimmunization rate in 218 consecutive patients - 128 from the Pediatric Department and 90 from the adult Hematology Department - undergoing hematopoietic stem cell transplantation (HSCT) between 1994 and 2000. In the pre-HSCT period, the pediatric patient...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704114

    authors： Perseghin P,Balduzzi A,Galimberti S,Dassi M,Baldini V,Valsecchi MG,Pioltelli P,Bonanomi S,Faccini P,Rovelli A,Pogliani EM,Uderzo C

    更新日期：2003-07-01 00:00:00

  • Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE).

    abstract：:Successful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosuppression to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemotherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700905

    authors： Oblon DJ,Paul S,Yankee R

    更新日期：1997-09-01 00:00:00

  • Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.

    abstract：:We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Po...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01156-y

    authors： Danylesko I,Shouval R,Shem-Tov N,Yerushalmi R,Jacoby E,Besser MJ,Shimoni A,Davidson T,Beider K,Mevorach D,Fried S,Nagler A,Avigdor A

    更新日期：2020-12-03 00:00:00

  • Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.

    abstract：:Fifteen patients with stage II-III multiple myeloma were intended to undergo two sequential cycles of myeloablative chemoradiotherapy with autologous bone marrow or blood stem cell transplantation after response to primary induction chemotherapy. BM grafts were used in 13 of the 15 first transplants whereas PBSC were ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Björkstrand B,Ljungman P,Bird JM,Samson D,Gahrton G

    更新日期：1995-03-01 00:00:00

  • Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.

    abstract：:Veno-occlusive disease of the liver (VOD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). To determine the incidence of, and the risk factors for the development of VOD, we performed a retrospective analysis of a series of 178 patients, who underwent allogeneic HSCT at...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703025

    authors： Moscardó F,Sanz GF,de La Rubia J,Jiménez C,Saavedra S,Regadera A,Andreu R,García I,Plumé G,Martínez J,Martín G,Jarque I,Sanz MA

    更新日期：2001-05-01 00:00:00

  • Prevention of autoimmune hearing loss in MRL/lpr mice by bone marrow transplantation.

    abstract：:We examined the effects of bone marrow transplantation (BMT) on immune-mediated inner ear diseases in MRL/Mp-lpr/lpr (MRL/lpr) mice, which manifest not only lupus nephritis but also sensorineural hearing loss (SNHL) at the age of 20 weeks. These mice were treated with cyclophosphamide (CY) and irradiation (5 Gy x 2), ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702636

    authors： Lee S,Iwai H,Sugiura K,Takeuchi K,Kushida T,Tomoda K,Inaba M,Yamashita T,Ikehara S

    更新日期：2000-10-01 00:00:00

  • Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.

    abstract：:Numerous studies have reported the feasibility and safety of autologous SCT (ASCT) in patients with multiple myeloma (MM) and mild to moderate renal impairment, but there are limited data in dialysis-dependent patients. In this retrospective study, we reviewed the toxicities and efficacy outcomes of 33  MM patients wi...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2014.226

    authors： St Bernard R,Chodirker L,Masih-Khan E,Jiang H,Franke N,Kukreti V,Tiedemann R,Trudel S,Reece D,Chen CI

    更新日期：2015-01-01 00:00:00

  • High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.

    abstract：:We report seven patients with germ cell tumors which either recurred following a minimum of two regimens of platinum-based chemotherapy or were refractory to cisplatin. The patients were treated with one or two courses of high dose carboplatin (CBDCA) and etoposide (VP-16) plus ifosfamide (IFX) with mesna uroprotectio...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Broun ER,Nichols CR,Tricot G,Loehrer PJ,Williams SD,Einhorn LH

    更新日期：1991-01-01 00:00:00

  • Childhood to adult transition and long-term follow-up after blood and marrow transplantation.

    abstract：:The use of hematopoietic stem cell transplantation or blood and marrow transplantation (BMT) is on the increase worldwide. With BMT's increasing utilization and increasing success, the number of BMT survivors in the United States alone is expected to surpass 500 000 by the year 2030. BMT survivors are susceptible to a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2015.228

    authors： Cupit MC,Duncan C,Savani BN,Hashmi SK

    更新日期：2016-02-01 00:00:00

  • Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method.

    abstract：:The present study analyses the influence of high-dose chemotherapy (HD) and autologous stem cell transplantation on natural and vaccine-induced specific immunity in breast cancer patients. Peripheral blood was collected from five breast cancer patients at serial time points in connection with treatment and in a follow...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703521

    authors： Svane IM,Nikolajsen K,Hansen SW,Kamby C,Nielsen DL,Johnsen HE

    更新日期：2002-04-01 00:00:00

  • High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.

    abstract：:Peripheral T cell lymphomas (PTCL) have a poorer prognosis after conventional treatment than do high-grade B cell lymphomas. The place for high-dose therapy (HDT) with autologous stem cell support in these patients is still not clear. Forty patients, 10 women and 30 men, median age 41.5 years (range 16-61) with PTCL w...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1702867

    authors： Blystad AK,Enblad G,Kvaløy S,Berglund A,Delabie J,Holte H,Carlson K,Kvalheim G,Bengtsson M,Hagberg H

    更新日期：2001-04-01 00:00:00

  • Successful HLA-identical sibling cord blood transplantation in a 6-year-old boy with leukocyte adhesion deficiency syndrome.

    abstract：:A 6-year-old boy with the severe form of the leukocyte adhesion deficiency syndrome (LAD) received a transplant of cord blood (CBT) from his HLA-identical brother. The donor was proved healthy by successful prenatal diagnosis. CBT was performed after conditioning with etoposide, busulfan and cyclophosphamide. After he...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Starý J,Bartůnková J,Kobylka P,Vávra V,Hrusák O,Calda P,Král V,Svorc K

    更新日期：1996-07-01 00:00:00

  • European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

    abstract：:We have retrospectively analyzed the impact of prognostic factors on the outcome of serologically HLA-matched unrelated donor (UD) BMT for CML. For this purpose, we have studied a cohort of 366 patients transplanted in Europe between January 1985 and December 1994. The median age of the 211 males and 155 females was 3...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700844

    authors： Devergie A,Apperley JF,Labopin M,Madrigal A,Jacobsen N,Carreras E,Prentice HG,Jouet JP,Kolb HJ,Herstenstein B,Bacigalupo A,Evensen SA,Ljungman P,de Witte T,Reiffers J,Nagler A,Clark RE,Goldman JM,Gratwohl A

    更新日期：1997-07-01 00:00:00

  • Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.

    abstract：:Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT. In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantita...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704290

    authors： Mandigers CM,Verdonck LF,Meijerink JP,Dekker AW,Schattenberg AV,Raemaekers JM

    更新日期：2003-12-01 00:00:00

  • Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.

    abstract：:Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705788

    authors： Barkholt L,Remberger M,Bodegård H,Ringdén O,Böttiger Y

    更新日期：2007-10-01 00:00:00

  • Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease.

    abstract：:Pentaglobin is a commercial immunoglobulin preparation which is enriched specifically for IgM and also contains antibodies that are capable of neutralizing endotoxins. Its potential use in treating patients with acute graft-versus-host disease (GVHD) was studied in a phase I/II study. Pentaglobin was administered at a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Klingemann HG,Barnett MJ,Reece DE,Shepherd JD,Phillips GL

    更新日期：1990-09-01 00:00:00

  • High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.

    abstract：:A recent shortage of melphalan has prompted the use of alternatives to BEAM (BCNU, Etoposide, Cytarabine, Melphalan) conditioning for autologous stem cell transplantion (ASCT). The BEAC (BCNU, Etoposide, Cytarabine, Cyclophosphamide) regimen has been employed as a conditioning regimen in lymphoma patients. However, th...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0196-3

    authors： Robinson SP,Boumendil A,Finel H,Dreger P,Sureda A,Hermine O,Montoto S

    更新日期：2018-12-01 00:00:00

  • A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions.

    abstract：:The extant literature documents burden among caregivers of patients undergoing a hematopoietic stem cell transplantation (HSCT), but little is known about the burden of caregivers of patients receiving outpatient and homebound HSCTs. This scoping study sought to evaluate what is known about the burden of the increasin...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2016.164

    authors： Applebaum AJ,Bevans M,Son T,Evans K,Hernandez M,Giralt S,DuHamel K

    更新日期：2016-11-01 00:00:00

  • Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.

    abstract：:Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41409-018-0154-0

    authors： Yahng SA,Park SS,Jeon YW,Yoon JH,Shin SH,Lee SE,Cho BS,Eom KS,Kim YJ,Lee S,Min CK,Kim HJ,Cho SG,Kim DW,Min WS,Lee JW

    更新日期：2018-10-01 00:00:00

  • CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.

    abstract：:A potential problem of autologous transplantation in the treatment of multiple myeloma (MM) is the infusion of tumor cells. CD34+ selection has been used to purge autografts in MM and it is also possible to reduce tumour cell contamination of autografts by cytotoxic drug therapy prior to peripheral blood stem cell (PB...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/sj.bmt.1702408

    authors： Dyson PG,Horvath N,Joshua D,Barrow L,Van Holst NG,Brown R,Gibson J,To LB

    更新日期：2000-06-01 00:00:00

  • Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

    abstract：:Trial outcomes comparing cytokine agents for PBSC mobilization in autologous hematopoietic transplant patients have been controversial. We performed a systematic review and meta-analysis of evidence available on pegfilgrastim vs filgrastim in chemo-cytokine mobilization. Electronic literature searches of PubMed, EMBAS...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,meta分析,评审

    doi：10.1038/bmt.2014.297

    authors： Kim MG,Han N,Lee EK,Kim T

    更新日期：2015-04-01 00:00:00

  • The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.

    abstract：:At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchos...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1701525

    authors： Humar A,O'Rourke K,Lipton J,Messner H,Meharchand J,Mahony J,Walker I,Wasi P,McGeer A,Moussa G,Chua R,Mazzulli T

    更新日期：1999-01-01 00:00:00

  • Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.

    abstract：:The use of mobilized peripheral blood (PB) stem cells for autologous transplantation initially generated much enthusiasm because of enhanced engraftment in comparison to marrow stem cells and avoidance of general anesthesia for the donor. Its application to the allogeneic setting seemed inevitable. For obvious ethical...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1702464

    authors： Gyger M,Stuart RK,Perreault C

    更新日期：2000-07-01 00:00:00

  • Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

    abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/bmt.2015.47

    authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

    更新日期：2015-06-01 00:00:00

  • Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial.

    abstract：:Suboptimal neutrophil and platelet recovery after unrelated donor umbilical cord blood transplantation (UCBT) may be due in part to an impaired microenvironment after intensive chemoradiotherapy. In an attempt to speed hematopoietic recovery, 15 pediatric patients with high-risk acute leukemia were enrolled on a singl...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.348

    authors： Macmillan ML,Blazar BR,DeFor TE,Wagner JE

    更新日期：2009-03-01 00:00:00

  • Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.

    abstract：:Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2015.234

    authors： Jedlickova Z,Schmid C,Koenecke C,Hertenstein B,Baurmann H,Schwerdtfeger R,Tischer J,Kolb HJ,Schleuning M

    更新日期：2016-05-01 00:00:00

  • Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.

    abstract：:Although neurocognitive impairment has been established as a major issue among cancer survivors, the real-world consequences of this impairment are unclear. This study investigated the relationship between neurocognitive functioning and medication management ability over time among 58 patients treated with allogeneic ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.2

    authors： Mayo S,Messner HA,Rourke SB,Howell D,Victor JC,Kuruvilla J,Lipton JH,Gupta V,Kim DD,Piescic C,Breen D,Lambie A,Loach D,Michelis FV,Alam N,Uhm J,McGillis L,Metcalfe K

    更新日期：2016-06-01 00:00:00

  • Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.

    abstract：:Graft failure (GF) remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti-HLA antibodies (DSA) was reported to be associated with an increased risk of GF after CBT, data are still limited. Thus, we conducted a retrospective analysis of recipients o...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0712-0

    authors： Fuji S,Oshima K,Ohashi K,Sawa M,Saito T,Eto T,Tanaka M,Onizuka M,Nakamae H,Shiratori S,Ozawa Y,Hidaka M,Nagamura-Inoue T,Tanaka H,Fukuda T,Ichinohe T,Atsuta Y,Ogata M

    更新日期：2020-04-01 00:00:00